/
RSS Feed
Months after declaring it was exploring strategic options following the failure of its lead experimental drug in a mid-stage study involving patients with stress urinary incontinence, GTx has agreed to be the vehicle that private oncology-focused biotech Oncternal Therapeutics is using to leap onto the Nasdaq.
James Breitmeyer
The new firm ? to be called Oncternal Therapeutics ? will trade under the symbol $ONCT, and Oncternal shareholders will hold three-fourths (75%) of the San Diego, Califor
